Company Profile
Natera Stock Price, News & Catalysts
- Ticker:
- NTRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
400.65 USD (-5.87%)
Close
Last updated: October 6, 2026
30.5B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, NTRA closed down 5.87% at $400.65. No new same-company headline was identified in the current news window.
Company overview
Cell-Free DNA and Genetic Testing Company
Natera develops molecular tests that use cell-free DNA, circulating tumor DNA, and other genomic signals to inform reproductive health, oncology, and organ transplantation. Its business combines centralized laboratory testing, proprietary algorithms, clinical evidence generation, physician education, and reimbursement development.
Reproductive Health Testing
The reproductive-health portfolio includes Panorama noninvasive prenatal testing, Horizon carrier screening, and Vistara single-gene screening. These products support risk assessment before and during pregnancy and represent one of the company's largest testing-volume businesses.
Oncology and Molecular Residual Disease
Signatera is a personalized circulating tumor DNA test used to detect molecular residual disease, monitor recurrence risk, and assess treatment response across multiple cancers. Altera provides tumor genomic profiling, allowing Natera to serve oncology workflows from therapy selection through longitudinal surveillance.
Organ Health
Prospera uses donor-derived cell-free DNA to monitor transplant recipients for signs of organ injury and rejection. The platform is applied across kidney, heart, lung, and multi-organ transplantation and is supported by clinical studies, guideline engagement, and payer coverage expansion.
Data and Biopharma Partnerships
Natera works with pharmaceutical companies and clinical investigators to incorporate molecular testing into trials and drug-development programs. Longitudinal datasets generated through its testing businesses also support biomarker discovery, treatment-response research, and real-world evidence.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Natera (NTRA)?
Natera (NTRA) most recently closed at 400.65 USD, a -5.87% move versus the previous session.
What is the market cap of Natera (NTRA)?
Natera currently has a market capitalization of 30.5B USD on BioPharmSignal.
What does Natera do?
Cell-Free DNA and Genetic Testing Company Natera develops molecular tests that use cell-free DNA, circulating tumor DNA, and other genomic signals to inform reproductive health, oncology, and organ transplantation. Its business combines centralized laboratory testing, proprietary algorithms, clinical evidence generation, physician education, and...
On which exchange is NTRA stock listed?
Natera (NTRA) is associated with NASDAQ, United States, Biopharma.
What is Cell-Free?
Cell-Free DNA and Genetic Testing Company Natera develops molecular tests that use cell-free DNA, circulating tumor DNA, and other genomic signals to inform reproductive health, oncology, and organ transplantation.
Which conditions is Natera targeting with Cell-Free?
Natera is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
What is Genetic?
Cell-Free DNA and Genetic Testing Company Natera develops molecular tests that use cell-free DNA, circulating tumor DNA, and other genomic signals to inform reproductive health, oncology, and organ transplantation.
What is Testing?
Cell-Free DNA and Genetic Testing Company Natera develops molecular tests that use cell-free DNA, circulating tumor DNA, and other genomic signals to inform reproductive health, oncology, and organ transplantation.